Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine
John S. Lambert(Mater Misericordiae University Hospital), Mary Glenn Fowler(Johns Hopkins University), Robert Maupin, James Bethel(Westat (United States)), Jean Whitehouse(Westat (United States)), William T. Shearer(Baylor College of Medicine), D.R. Harris(Westat (United States)), E. Richard Stiehm(European Respiratory Society), D. Heather Watts(National Institutes of Health), Jorge Gandía(Hospital de Sant Pau), Lynne Mofenson(Elizabeth Glaser Pediatric AIDS Foundation), Eleanor Jiménez(University of Miami), M Silió(University of Maryland, Baltimore), Alice Stek(University of Southern California), Hunter Hammill(University of Southern California), Andrea Kovacs(University of Southern California), Gwen Scott(University of Maryland, Baltimore), Mary Jo O’Sullivan(University at Buffalo, State University of New York), Russell Van Dyke(Cancer Research And Biostatistics)
Cited by 80
Related Papers
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
|The Lancet|1999|1.7k
Maternal and Perinatal Outcomes Associated with a Trial of Labor after Prior Cesarean Delivery
|New England Journal of Medicine|2004|1.3k
Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer
|New England Journal of Medicine|2006|985